Therapeutic exposure Potential late effect Vincristine, vinblastine Peripheral neuropathy, Raynaud’s phenomenon Corticosteroids Cataracts, osteopenia, osteoporosis, avascular necrosis Mercaptopurine Hepatic dysfunction, veno-occlusive disease Methotrexate (Systemic) osteopenia, osteoporosis, renal dysfunction, hepatic dysfunction…
Fig. 26.1 Potential problems encountered by AYA during and following treatment for cancer according to the International Classification of Functioning, Disability and Health 26.2 Body Structure and Function Impairments of…
Agent Cumulative dose associated with azoospermia Cyclophosphamide >5–7.5 g/m2 associated with abnormal semen parameters, >19 g/m2 consistently result in azoospermia Ifosfamide >60 g/m2 Procarbazine >4 g/m2 Busulfan >600 mg/m2 Melphalan…
© Springer International Publishing 2017Archie Bleyer, Ronald Barr, Lynn Ries, Jeremy Whelan and Andrea Ferrari (eds.)Cancer in Adolescents and Young AdultsPediatric Oncology10.1007/978-3-319-33679-4_23 23. Psychosocial Issues in Adolescent and Young Adult Patients and Survivors Anthony Penn1 , Aura Kuperberg2 and Brad J. Zebrack3 (1)…
Fig. 1.1 Landmark events in the development of AYA oncology in North America. CCG Children’s Cancer Group, NCI National Cancer Institute, PRG Progress Review Group, JAYAO Journal of Adolescent and…
Age group (years) Incidence of Hodgkin lymphoma in the United Statesa Percent Hodgkin lymphoma of all cancers Estimated number of annual new cases of Hodgkin lymphoma Males Females Males (%)…
Fig. 13.1 A D1 solitary osteolytic metastasis; the 56-year- old patient underwent en bloc vertebrectomy and reconstruction with homoplastic diaphysis segment filled with the autoplastic morcellized bone, plates, and screws;…
Fig. 7.1 Pathway of choline metabolism in normal and cancer cell (Cho choline, ChAT choline acetyltransferase, ACho acetylcholine, ChoK choline kinase, CMP cytidylate, DAG diacylglycerol, PCho phosphocholine, CDP diphosphocholine, PPi…
Fig. 9.1 18F-FACBC positive bone metastases in high-risk prostate cancer at staging evaluation. A 71-year-old patient diagnosed with high-risk prostate cancer (PSA 6.8 ng/ml; cT2; GS 4 + 4) underwent…
Fig. 18.1 Signs of responding vertebral metastases visible on T1w MR imaging (Modified from Lecouvet et al. [31]) 1. Shrinkage or progressive fading of the marrow signal intensity abnormalities …
